Download PDFPDF

Bloodless treatment of infants with haemolytic disease
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    D-penicillamine treatment in Rh-Haemolytic Disease of a newborn

    Dear Editor,

    Reflecting to the letter of Mark P Tighe, et al.[1] we would like to report our case with rhesus-haemolytic disease treated with D-penicillamine (DPA) and phototherapy without exchange transfusion:

    We recently cared for a term infant boy (blood group B, Rh-positive, weighed 3100 gm) who was born at 37. gestation to a 33-year old, blood group B, Rh-negativ mother. During pregnancy the indirect Coom...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Bloodless treatment of infants with rhesus-haemolytic disease
    • Mark P Tighe, Paediatric Specialist Registrar
    • Other Contributors:
      • Alyson O'Donnell, Mary Morgan

    Dear Editor,

    We read with interest the letter discussing bloodless treatment of infants with haemolytic disease [1], which highlighted the successful use of erythropoietin and D-penicillamine. We wish to contribute to the discussion of the use of erythropoietin with a case report:

    Mrs M (G2 P1), a Jehovah’s Witness, presented at 12 weeks with high avidity anti-D antibodies (9.5 I.U.), and anti-JKa antib...

    Show More
    Conflict of Interest:
    None declared.